News for Editas Medicine, Inc. (0IFK.L)

Erick J. Lucera to Step Down as CFO to pursue another opportunity Senior Vice President of Finance Amy Parison Appointed CFO CAMBRIDGE, Mass., March 20, 2025

**media[572461,572462]**

Editas Medicine, Inc. (NASDAQ:EDIT) Barclays 27th Annual Global Healthcare Conference March 11, 2025 9:00 AM ETCompany ParticipantsGilmore O’Neill -...

Editas Medicine, Inc. (NASDAQ:EDIT) Leerink Partners Global Healthcare Conference March 10, 2025 9:20 AM ETCompany ParticipantsGilmore O’Neill - President...

Editas Medicine, Inc. (NASDAQ:EDIT) TD Cowen 45th Annual Health Care Conference March 3, 2025 2:30 PM ETCompany ParticipantsGilmore O'Neill - Chief...

CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. ( EDIT), a pioneering gene editing company focused on developing transformative medi

China-based WORK Medical Technology Group LTD (WOK) is up over 94 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

Editas Medicine, Inc. (NASDAQ:EDIT) 43rd Annual JPMorgan Healthcare Conference Call January 15, 2025 2:15 PM ETCompany ParticipantsGilmore O'Neill -...

CAMBRIDGE, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. ( EDIT), a leading gene editing company, today announced that the Company's Presiden

Brokerages downgrade gene editing company Editas to 'hold', shares slump 23%

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please ...

Focus on in vivo CRISPR-edited medicines based on Editas researchers' recent scientific progress in multiple tissues: Achieved pre-clinical in vivo proof of co

**media[487536]**

Poster presentation at ASH on Monday, December 9 at 6:00 p.m. PT / 9:00 p.m. ET CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. ( E

Editas Medicine, Inc. (NASDAQ:EDIT) 7th Annual Evercore HealthCONx Conference December 3, 2024 1:20 PM ETCompany ParticipantsErick Lucera - Executive Vice...

Editas Medicine, Inc. (EDIT) experienced a significant stock drop of 5.13%, trading at $2.13 with a volume of 1.33438 million shares. The turnover rate was 1.62

Editas Medicine, Inc. (EDIT), a clinical-stage genome editing company, experienced a significant stock price drop of 5.24%. The stock is currently trading at $2

Editas Medicine stock hits 52-week low at $2.7 amid market challenges

Achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells (HSPCs) using Editas Medicine’s proprietary...